Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

9/25/23 11:01:32 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $IMVT alert in real time by email

NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will report initial IMVT-1402 Phase 1 results on Tuesday, September 26, 2023. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.

To participate in the conference call, please register in advance here. To access the live and archived webcast, please visit Immunovant's website at https://www.immunovant.com/investors/news-events. The archived webcast will be available for a limited time on the Company's website.

About Immunovant, Inc.

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit www.immunovant.com.

Contact:

Chau Cheng, PhD, MBA

Vice President, Investor Relations

Immunovant, Inc.

[email protected]

Get the next $IMVT alert in real time by email

Date	Price Target	Rating	Analyst
10/10/2024	$36.00	Outperform	Raymond James
10/9/2024	$47.00 → $53.00	Outperform	Oppenheimer
3/28/2024	$50.00	Outperform	Oppenheimer
3/13/2024	$50.00	Buy	Goldman
2/20/2024	$51.00	Overweight	JP Morgan
2/15/2024	$55.00	Outperform	Wolfe Research
12/12/2023	$50.00	Buy	Deutsche Bank
10/13/2023	$18.00 → $55.00	Neutral → Buy	UBS

Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

Chat with this insight

Recent Analyst Ratings for $IMVT

$IMVT Press Releases

Fastest customizable press release news feed in the world

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

$IMVT Financials

Live finance-specific insights

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

$IMVT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Immunovant Inc.

SEC Form SC 13G/A filed by Immunovant Inc. (Amendment)

SEC Form SC 13G filed by Immunovant Inc.

$IMVT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Roivant Sciences Ltd. was granted 4,473,684 shares and bought $58,000,008 worth of shares (1,526,316 units at $38.00), increasing direct ownership by 8% to 79,805,331 units (SEC Form 4)

$IMVT Leadership Updates

Live Leadership Updates

$IMVT Market Insights

Live Market Insights

$IMVT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

Immunovant Appoints Mark Levine as Chief Legal Officer

Immunovant Appoints Renee Barnett as Chief Financial Officer

Cantor Fitzgerald Reiterates Overweight on Immunovant

Cantor Fitzgerald Reiterates Overweight on Immunovant

Oppenheimer Maintains Outperform on Immunovant, Lowers Price Target to $46

Chief Operating Officer Gloria Melanie was granted 109,956 shares (SEC Form 4)

SEC Form 3 filed by new insider Gloria Melanie

Chief Legal Officer Levine Mark S. sold $128,780 worth of shares (4,361 units at $29.53), decreasing direct ownership by 1% to 322,878 units (SEC Form 4)

$IMVT SEC Filings

SEC Form 10-Q filed by Immunovant Inc.

Immunovant Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

Immunovant Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

$IMVT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Raymond James resumed coverage on Immunovant Sciences with a new price target

Oppenheimer reiterated coverage on Immunovant Sciences with a new price target

Oppenheimer initiated coverage on Immunovant Sciences with a new price target

Recent Analyst Ratings for
$IMVT

$IMVT
Press Releases

$IMVT
Financials

$IMVT
Large Ownership Changes

$IMVT
Insider Purchases

$IMVT
Leadership Updates

$IMVT
Market Insights

$IMVT
Insider Trading

$IMVT
SEC Filings

$IMVT
Analyst Ratings